Guidance for Pediatric Familial Hypercholesterolemia 2017

Area of Science:

• Pediatric Cardiology
• Genetics
• Atherosclerosis Research

Background:

• Familial Hypercholesterolemia (FH) is a common genetic disorder characterized by high LDL cholesterol levels from birth.
• Early-onset atherosclerosis in FH patients necessitates timely diagnosis and treatment to mitigate long-term cardiovascular risks.
• Current management strategies require updated guidance for pediatric populations.

Purpose of the Study:

• To establish a consensus statement for the diagnosis and management of pediatric Familial Hypercholesterolemia (FH).
• To provide updated guidance for the Japan Pediatric Society and Japan Atherosclerosis Society.
• To improve the long-term prognosis of children diagnosed with FH.

Main Methods:

• Consensus development by a Joint Working Group of the Japan Pediatric Society and Japan Atherosclerosis Society.
• Review of diagnostic criteria for pediatric heterozygous FH (LDL-C ≥140 mg/dL, family history).
• Recommendations for lifestyle modifications, pharmacotherapy (statins), and monitoring for homozygous FH.

Main Results:

• Diagnostic criteria for pediatric heterozygous FH established.
• Pharmacotherapy, primarily statins, recommended for children ≥10 years with persistent LDL-C >180 mg/dL.
• LDL apheresis indicated for homozygous FH patients unresponsive to pharmacotherapy.

Conclusions:

• Early diagnosis and intervention are critical for improving the prognosis of pediatric FH.
• A stepwise approach involving lifestyle changes and pharmacotherapy is recommended.
• Regular assessment and monitoring are essential for managing FH in children.